MHRA does not look at the stock price - they only look at the trials and the science. Based on the latter, they should get approval there. I see a similar path to MELA where they got EU approval and then FDA will soften its stance (when questioned on its decision) and the stock will see $4s early next year. It is sitting at cash value right now and so there is little downside for the short term and only upside from here on any positive news...